secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0000950170-23-033933
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak discontinues tarcocimab after Phase 3 DME studies fail to meet endpoints; DAYLIGHT meets primary endpoint
--------------------------------------------------------------------------------

- Cash and equivalents $379M as of June 30, 2023 (unaudited).
- DAYLIGHT study in wet AMD met primary endpoint of non‑inferior visual acuity gains vs aflibercept.
- GLEAM and GLIMMER DME studies did not meet primary efficacy endpoint; tarcocimab letters gained 6.4 vs 10.3 (GLEAM) and 7.4 vs 12.2 (GLIMMER).
- Cataract adverse events at 19% on tarcocimab vs 9% on aflibercept in pooled DME safety population; no vasculitis or occlusion.
- Company discontinues further development of tarcocimab based on these data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/0000950170-23-033933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/kod-20230724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer